Ancora Heart announced it has reached the first enrollment milestone in its CORCINCH-HF pivotal trial evaluating the AccuCinch Transcatheter Left Ventricular Restoration System for patients with heart failure with reduced ejection fraction (HFrEF). The trial has now enrolled 250 randomized patients. Data collected at six months will support the … [Read more...] about Ancora Heart reaches enrollment milestone in pivotal heart failure device trial
Ancora Heart
Ancora Heart, Egnite partner on AccuCinch trial enrollment
Ancora Heart announced that it entered into a strategic partnership with Egnite to accelerate clinical trial enrollment. The partnership centers around the Ancora Heart CORCINCH-HF pivotal clinical trial. It evaluates the safety and efficacy of the AccuCinch ventricular restoration system. Together, the companies aim to combine cutting-edge … [Read more...] about Ancora Heart, Egnite partner on AccuCinch trial enrollment
Ancora Heart appoints David Tucker as CFO
Ancora Heart today announced it appointed David Tucker as chief financial officer. Tucker will be responsible for the Santa Clara, California-based company's financial strategies and operations as it enrolls patients in the Corcinch-HF pivotal clinical trial of its AccuCinch ventricular restoration system. “David’s experience includes … [Read more...] about Ancora Heart appoints David Tucker as CFO
Ancora Heart names Mark Miles as chief commercial officer
Ancora Heart today announced it appointed Mark Miles as chief commercial officer. Miles will oversee the Santa Clara, California-based company's commercialization strategy for the AccuCinch ventricular restoration system, a transcatheter procedure to treat enlarged left ventricles in the heart. “Mark’s track record in commercialization and … [Read more...] about Ancora Heart names Mark Miles as chief commercial officer
Ancora Heart raises $80M for ventricular restoration system
Ancora Heart announced today that it raised $80 million in equity financing for its AccuCinch ventricular restoration system. Santa Clara, Calif.-based Ancora Heart said in a news release that funds raised in the equity round are earmarked for the acceleration of the Corcinch-HF pivotal clinical study of the AccuCinch system for treating … [Read more...] about Ancora Heart raises $80M for ventricular restoration system
Ancora Heart says enrollment has started for AccuCinch pivotal trial
Ancora Heart this week said it has enrolled the first patient in its AccuCinch Ventricular Restoration System pivotal trial. AccuCinch is a flexible implant that is attached to the inner wall of the left ventricle and then cinched. It is designed to reduce the size of the left ventricle, reduce ventricular wall stress and support and strengthen … [Read more...] about Ancora Heart says enrollment has started for AccuCinch pivotal trial
